Nektar Therapeutics’s filing revealed that its President & CEO ROBIN HOWARD W unloaded Company’s shares for reported $15598.0 on Aug 16. In the deal valued at $0.78 per share,19,998 shares were sold. As a result of this transaction, ROBIN HOWARD W now holds 919,799 shares worth roughly $ 0.54 million.
Then, Zalevsky Jonathan sold 9,703 shares, generating $7,568 in total proceeds. Upon selling the shares at $0.78, the Chief R&D Officer now owns 283,685 shares.
Before that, Wilson Mark Andrew sold 7,221 shares. Nektar Therapeutics shares valued at $5,632 were divested by the Chief Legal Officer at a price of $0.78 per share. As a result of the transaction, Wilson Mark Andrew now holds 250,959 shares, worth roughly $0.15 million.
Jefferies upgraded its Nektar Therapeutics [NKTR] rating to a Hold from a an Underperform in a research note published on Tuesday, May 10, 2023; the price target was decreased to $1 from $1.50. PT values the company’s stock at a premium of 41.0 to its Tuesday closing price.
Price Performance Review of NKTR
On Tuesday, Nektar Therapeutics [NASDAQ:NKTR] saw its stock fall -1.68% to $0.59. On the same session, the stock had its day’s lowest price of $0.5813, but rose to a high of $0.608. Over the last five days, the stock has lost -9.66%. Nektar Therapeutics shares have fallen nearly -74.05% since the year began. Nevertheless, the stocks have fallen -85.41% over the past one year. While a 52-week high of $4.36 was reached on 02/07/23, a 52-week low of $0.51 was recorded on 07/26/23. SMA at 50 days reached $0.6366, while 200 days put it at $1.4249. A total of 1.42 million shares were traded, compared to the trading of 1.35 million shares in the previous session.
Levels Of Support And Resistance For NKTR Stock
The 24-hour chart illustrates a support level at 0.5759, which if violated will result in even more drops to 0.5652. On the upside, there is a resistance level at 0.6026. A further resistance level may holdings at 0.6186. The Relative Strength Index (RSI) on the 14-day chart is 40.85, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.0669, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 97.99%. Stochastics %K at 3.35% indicates the stock is a buying.
How much short interest is there in Nektar Therapeutics?
A steep rise in short interest was recorded in Nektar Therapeutics stocks on Aug 14, 2023, growing by 1.87 million shares to a total of 7.15 million shares. Yahoo Finance data shows the prior-month short interest on Jul 13, 2023 was 5.28 million shares. There was a rise of 26.15%, which implies that there is a positive sentiment for the stock. In spite of short shares comprising just 7.76% of the overall stock float, the days-to-cover ratio (short ratio) rose to 0.53.
Nektar Therapeutics [NKTR] – Who Are The Largest Shareholders?
In filings from RA Capital Management LP, it is revealed that the company now owns 18,700,000 shares, or roughly 9.88% of the outstanding NKTR shares. Additionally, Deep Track Capital LP increased 931.03% of its stake after which the total value it holdings stand at $9,633,777, while The Vanguard Group, Inc. reduced -38.33% of its stake to hold $6.43 million in the firm. At present, PRIMECAP Management Co. is holding 8,149,876 shares valued at $4.37 million. Citadel Advisors LLC owned 7,500,000 shares of the company at the time of its most recent 13F filing, worth $4.02 million.
According to FactSet, Nektar Therapeutics’s share price will average $2.35 in the next year, based on opinions of analysts polled by the firm. This is up nearly 191.67 percent from its previous closing price of $0.60. Analysts expect Nektar Therapeutics stock to reach the higher price of $6.00, while the lowest price estimate is $0.60.